

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT**

### **RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE THREE MONTHS ENDED 31 MARCH 2023**

On 12 April 2023, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2023.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 12 April 2023, Dong-E-E-Jiao released its results estimate for the three months ended 31 March 2023, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the three months ended 31 March 2023 is estimated to range from approximately RMB220 million to RMB245 million (as compared to the same period last year of approximately RMB114.6757 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB206 million to RMB220 million (as compared to the same period last year of approximately RMB91.5146 million), and basic earnings per share is estimated to range from approximately RMB0.34 per share to approximately RMB0.38 per share (as compared to the same period last year of approximately RMB0.1781 per share) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

In 2023, focusing on the key theme of “growth and efficiency,” Dong-E-E-Jiao will further promote value restructuring, accelerate business restructuring, deepen organizational restructuring, and strengthen the restructuring of our corporate culture. Dong-E-E-Jiao will continue to consolidate its position as a top-tier brand with “Zi Bu Guo Bao Dong-E-E-Jiao,” while adhering to a consumer-centric approach and driving the development of both “medicine” and “health consumer products.” Dong-E-E-Jiao will invest in scientific research and innovation, continue to solidify the role of E-Jiao blocks and compound E-Jiao paste businesses, launch its strategy for the broad category of compound E-Jiao paste products, expand the regional layout of its “Taohuajie” E-Jiao cake products, and steadily improve its business performance.

In the future, guided by its dual-wheel drive mode, Dong-E-E-Jiao will fully grasp new opportunities in the development of traditional Chinese medicine, vigorously promote traditional Chinese medicine culture, systematically build evidence-based medical academic system, focus on upgrading its E-Jiao products, and improve its layout for health supplements. Dong-E-E-Jiao will continue to enrich their product offerings with “E-Jiao+” and “+E-Jiao” combinations, comprehensively promote the reconstruction of Dong-E-E-Jiao’s organizational and system capabilities, and strive to become a leader in the health supplement industry.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the quarterly report for the three months ended 31 March 2023 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group. **Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

For further details of the Dong-E-E-Jiao quarterly financial information, please refer to the quarterly report for the three months ended 31 March 2023 to be published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange ([www.szse.cn](http://www.szse.cn)).

By Order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Shenzhen, 13 April 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*